Finance Watch: Latest Slate Of VC Mega-Deals Led By China-Based Biopharmas
Chime Biologics, AffaMed, Brii Closed $100m-Plus Rounds
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
You may also be interested in...
Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.
Public Company Edition: It took 256 days for 2021 to surpass the 2020 record of 86 biopharma initial public offerings in the US in one year. Also, Procaps raised $115m ahead of its SPAC merger and aTyr and bluebird raised $75m each.
With a CD8-targeting IL-2 mutein as its lead program, the start-up is developing cis-targeted immunotherapies that selectively target two molecules on the same immune cell for improved efficacy and safety.